Data Science

Q&A with Candriam’s Thomson: A science-led, transparent regulatory process is key for biotech sector

Cuts to US FDA funding are fuelling fears of delays to drug approvals that could kickstart a biotech stock selloff

April 17, 2025

Search PA Future

Cookie Policy
Privacy Policy
Terms and Conditions
Contact

Published by MA Financial Media Ltd (part of Mark Allen),
St Jude’s Church, London SE24 0PB Copyright (c) 2024.

The investment industry is at a crossroads, facing rapid technological change, diverging policies, and rising transparency demands.

PA Future delivers sharp analysis, exclusive interviews, and unfiltered insights on the forces reshaping investment management – from AI and sustainable finance to regulation and corporate culture.

We don’t just report on change – we challenge the industry to innovate and lead. This is PA Future.

Data Science

Q&A with Candriam’s Thomson: A science-led, transparent regulatory process is key for biotech sector